<DOC>
	<DOC>NCT00885378</DOC>
	<brief_summary>The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.</brief_summary>
	<brief_title>Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes 1878 years of age Taking stable twice daily (BID) dosing of metformin IR (at least 1500 mg) for at least 8 weeks A1C: 710% Cpeptide: ≥ 0.8 ng/mL Body mass index (BMI): ≤45 kg/m^2 Women of childbearing potential unable or unwilling to use acceptable birth control Women who are pregnant or breastfeeding Fasting plasma glucose (FPG) &gt;270 mg/dL Significant cardiovascular history Symptoms of poorly controlled diabetes History of diabetic ketoacidosis or hyperosmolar nonketotic coma Insulin therapy within one year of screening Cardiovascular even within the prior 6 months New York Heart Association Stage III/IV congestive heart failure and/or known left ventricular ejection fraction &lt;=40% Significant history of renal or hepatic disease History of a psychiatric disorder, alcohol or drug abuse within the previous year Treatment with potent CYP3A4 inhibitors or inducers Immunocompromised participants Active liver disease or clinically significant abnormal hepatic, renal , endocrine, metabolic, or hematological screening tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>